Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Raw Materials (2020 - 2025)

IceCure Medical (ICCM) has disclosed Raw Materials for 5 consecutive years, with $1.4 million as the latest value for Q4 2024.

  • On a quarterly basis, Raw Materials rose 1.22% to $1.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.4 million, a 1.22% increase, with the full-year FY2024 number at $1.4 million, up 1.22% from a year prior.
  • Raw Materials was $1.4 million for Q4 2024 at IceCure Medical, up from $1.4 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $1.6 million in Q4 2022 to a low of $380000.0 in Q4 2020.
  • A 5-year average of $1.1 million and a median of $1.4 million in 2023 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: skyrocketed 122.44% in 2022, then fell 11.17% in 2023.
  • IceCure Medical's Raw Materials stood at $380000.0 in 2020, then skyrocketed by 85.26% to $704000.0 in 2021, then skyrocketed by 122.44% to $1.6 million in 2022, then dropped by 11.17% to $1.4 million in 2023, then grew by 1.22% to $1.4 million in 2024.
  • Per Business Quant, the three most recent readings for ICCM's Raw Materials are $1.4 million (Q4 2024), $1.4 million (Q4 2023), and $1.6 million (Q4 2022).